Stock listing

OTC:GRTX Galera Therapeutics, Inc. Stock

Follow Galera Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:GRTX

$12.00 USD -0.15 (-1.2%)

Close on Nov 20, 2026 · Data provided by Twelve Data

Past year +200.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$11.76 – $12.30 USDNov 20, 2026
Volume
336,160 sharesNov 20, 2026
Market cap
—Left out: price × shares is far from the company's reported size
52-week range
$4.02 – $50.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.80M USDMedian day 377,921 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Galera Therapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:GRTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.00-0.15-1.2%$12.01$12.30$11.76336,160
$12.15-0.06-0.5%$12.30$12.81$11.99361,890
$12.21+0.14+1.2%$12.00$13.25$11.73681,210
$12.07-0.29-2.3%$12.26$12.51$11.88282,022
$12.36-0.20-1.6%$12.50$12.71$11.85727,866
$12.56+0.08+0.6%$12.37$13.00$11.80314,042
$12.48-0.40-3.1%$12.99$13.04$12.00328,742
$12.88-0.86-6.3%$13.77$14.00$12.82663,428
$13.74+0.03+0.2%$13.39$14.03$12.74744,000
$13.71-0.155-1.1%$13.34$14.21$12.401,143,735
$13.87+4.265+44.4%$10.41$14.77$9.712,092,191
$9.60-1.39-12.6%$10.98$10.98$9.60778,314
$10.99-2.24-16.9%$13.55$13.75$10.60544,019
$13.23-1.20-8.3%$14.23$14.97$13.01626,849
$14.43-0.36-2.4%$14.62$14.92$13.48526,048
$14.79+0.27+1.9%$14.55$15.52$13.66563,091
$14.52-0.07-0.5%$14.67$15.87$14.30248,152
$14.59+0.34+2.4%$13.38$15.00$13.38411,962
$14.25+0.39+2.8%$13.72$14.31$13.20397,721
$13.86-0.12-0.9%$14.07$14.30$13.16204,801
$13.98+0.04+0.3%$13.83$14.17$13.43279,756
$13.94+0.01+0.1%$14.10$14.50$13.74174,494
$13.93+0.68+5.1%$13.34$14.60$13.34332,844
$13.25+1.31+11.0%$11.97$13.47$11.57410,945
$11.94+0.17+1.4%$11.75$12.00$11.52106,444
$11.77-0.43-3.5%$12.31$12.46$11.62297,719
$12.20-0.02-0.2%$12.31$12.67$12.06240,337
$12.22+0.23+1.9%$12.00$12.67$11.79298,258
$11.99-0.80-6.3%$12.96$13.18$11.86377,259
$12.79-0.21-1.6%$13.13$13.21$12.61420,010
$13.00+0.76+6.2%$12.25$13.95$12.25532,207
$12.24-0.96-7.3%$13.14$13.39$12.07517,206
$13.20-0.02-0.2%$13.02$13.88$12.80359,041
$13.22-0.62-4.5%$13.84$14.42$13.00288,797
$13.84+0.25+1.8%$13.45$14.26$13.09199,185
$13.59+0.27+2.0%$13.07$13.90$13.07228,988
$13.32-0.41-3.0%$13.86$14.68$13.16299,804
$13.73-0.85-5.8%$14.58$14.70$13.11351,595
$14.58+1.21+9.1%$13.28$15.38$12.80378,583
$13.37+0.51+4.0%$12.91$13.73$12.33912,961
$12.86-0.55-4.1%$13.54$13.70$12.16454,560
$13.41-1.85-12.1%$15.27$15.66$13.20426,630
$15.26-1.74-10.2%$17.10$17.10$15.25582,606
$17.00-0.33-1.9%$17.44$17.97$16.711,151,577
$17.33-0.42-2.4%$18.08$18.21$17.141,104,889
$17.75+0.25+1.4%$17.61$18.16$17.363,974,351
$17.50+0.35+2.0%$17.16$18.19$17.16829,641
$17.15+0.15+0.9%$17.29$18.10$16.911,167,024
$17.00-1.10-6.1%$18.17$18.75$17.00472,267
$18.10+0.30+1.7%$18.39$19.00$17.84455,457
$17.80+0.64+3.7%$17.23$18.49$17.17392,799
$17.16-1.52-8.1%$18.65$19.55$17.00454,209
$18.68-0.05-0.3%$18.16$19.97$18.16332,204
$18.73+1.91+11.4%$16.98$19.87$16.98599,438
$16.82-0.27-1.6%$17.26$19.00$16.57140,120
$17.09+0.09+0.5%$16.85$18.06$16.15136,232
$17.00-0.04-0.2%$17.35$18.01$16.25126,347
$17.04-0.47-2.7%$17.18$18.09$16.2779,263
$17.51+1.21+7.4%$16.55$17.99$15.53142,522
$16.30-0.74-4.3%$16.58$18.11$15.85260,571
$17.04-1.36-7.4%$17.80$18.72$16.8065,063
$18.40-0.60-3.2%$18.32$19.20$17.79118,409
$19.00+0.30+1.6%$19.29$19.44$18.50155,712
$18.70-1.20-6.0%$20.39$21.98$17.80133,102
$19.90-0.29-1.4%$20.47$21.33$18.441,449,276
$20.19+0.19+1.0%$20.20$21.03$19.7074,359
Ticker
OTC:GRTX
Asset type
Stock
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Galera Therapeutics, Inc. news

Galera Therapeutics, Inc. on 6ix

News releases
2 in the last 12 months · 4 in all · newest Apr 14, 2026 · oldest 2025
Decks
13 decks · latest Jun 2, 2026

Valuation

price Nov 20, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
0.79

Team and board

OfficerRole
Caroline CodeVP Corporate Development & Investor Relations

Decks

DeckKindSlidesDate
Merger or Acquisition (June 2026)Merger or acquisition19 slidesJun 2, 2026
Merger or Acquisition (April 2026)Merger or acquisition17 slidesApr 14, 2026
Investor Presentation (December 2024)Investor deck35 slidesDec 31, 2024
Investor Presentation (October 2022)Investor deck48 slidesOct 26, 2022
Technical Presentation (December 2021)Technical18 slidesDec 14, 2021
Investor Presentation (September 2021)Investor deck50 slidesSep 8, 2021
Investor Presentation (April 2021)Investor deck44 slidesApr 28, 2021
Investor Presentation (January 2021)Investor deck47 slidesJan 6, 2021
Investor Presentation (November 2020)Investor deck41 slidesNov 10, 2020
Investor Presentation (September 2020)Investor deck32 slidesSep 16, 2020
All 13 decks
DeckKindSlidesDate
Investor Presentation (September 2020)Investor deck29 slidesSep 9, 2020
Investor Presentation (July 2020)Investor deck29 slidesJul 14, 2020
Investor Presentation (May 2020)Investor deck33 slidesMay 12, 2020

Open Decks

Financings

RaiseDate
Private placement of private placement financing
Announced: US$350M · Leerink Partners +4
Dealers: Leerink Partners, TD Cowen, Piper Sandler, William Blair, LifeSci Capital
Buyers: Balyasny Asset Management; Caligan Partners LP; Eventide Asset Management; Nantahala Capital; Octagon Capital; Redmile; Spruce Street Capital; Trails Edge Capital Partners; Atlas Venture; Deep Track Capital; Foresite Capital; Janus Henderson Investors
Use of proceeds: Fund the combined company into the second half of 2028 and through clinical milestones for OBX-115, including NSCLC Phase 1 data and melanoma registration-enabling data
Apr 14, 2026

Open Financings · Read by 6ix AI from the company's releases

Cap table

Built by 6ix from Galera Therapeutics, Inc.’s releases · as of Apr 14, 2026

Common shares
377,311
Fully diluted
377,311

Fully diluted

LineShares
Common shares377,311

Share count over time

CountShares
Nov 22, 2026377,311

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Diversified Equity Alpha Master Portfolio7<0.01%US$1Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Emerald Bioventures, LLC30.20%61MMay 15, 2026Schedule 13D
Parvinder Singh Hyare6.65%13.5MMay 15, 2026Schedule 13D
CHANG NANCY T5.90%8.92MDec 30, 2024Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Nancy Chang
Other companies: Immix Biopharma, Inc. (Independent Director · Since at least Sep 8, 2025); W&T Offshore, Inc. (Director · Since at least Apr 28, 2023); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); SciClone Pharmaceuticals Inc (Director · Sep 17, 2013 – Oct 13, 2017 · Past); Charles River Laboratories International, Inc. (Director · Oct 24, 2007 – May 7, 2010 · Past); Tanox Inc (Director · Dec 31, 2005 – Nov 2, 2006 · Past)
Director · Since at least Dec 30, 2024
Lawrence M. Alleva
Other companies: Mersana Therapeutics Inc (Director · Since at least Sep 5, 2017); Bright Horizons Family Solutions Inc. (Board Member · Since at least May 12, 2016); Adaptimmune Therapeutics PLC (Chairman and Non-Executive Director · Since at least Jan 1, 2016); Tesaro Inc (Director · Jun 1, 2016 – Jan 22, 2019 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past)
Director · Since at least Nov 6, 2019
Emmett Cunningham
Other companies: NovaBridge Biosciences (Director · Since at least Mar 18, 2026); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Lumos Pharma Inc (Director · Mar 18, 2020 – Apr 3, 2020 · Past); Venus Concept Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past)
Director · Nov 6, 2019 – Jun 14, 2023 · Past
Jennifer Evans Stacey
Other companies: Neogen Corporation (Chief Legal Officer · Since at least Apr 8, 2026); Context Therapeutics Inc. (Independent Director · Since at least Oct 19, 2021); Antares Pharma Inc (SVP, General Counsel & Secty · May 29, 2014 – May 28, 2015 · Past); Auxilium Pharmaceuticals Inc (Executive VP & General Counsel · Jun 6, 2006 – Feb 28, 2011 · Past)
See Remarks · Oct 8, 2021 – Feb 25, 2023 · Past
Arthur Fratamico
Other companies: Panbela Therapeutics, Inc. (Director · Dec 1, 2020 – Mar 27, 2023 · Past); Vitae Pharmaceuticals Inc (Chief Business Officer · Sep 24, 2014 – Oct 24, 2016 · Past); Flexion Therapeutics Inc (Chief Business Officer · Feb 11, 2014 – Feb 11, 2014 · Past)
Chief Business Officer · Nov 6, 2019 – Jan 26, 2021 · Past
Michael Powell
Other companies: Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Checkmate Pharmaceuticals Inc (Director · Aug 6, 2020 – May 31, 2022 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 5, 2019 · Past)
Director · Nov 6, 2019 – Jun 14, 2023 · Past
Chris Degnan
Other companies: UroGen Pharma Ltd. (Chief Financial Officer · Since at least Oct 8, 2024); Verrica Pharmaceuticals Inc. (Chief Financial Officer · Jun 14, 2018 – Feb 28, 2019 · Past)
Chief Financial Officer · Nov 6, 2019 – Mar 13, 2023 · Past
Eugene Kennedy
Other companies: Aprea Therapeutics, Inc. (Chief Medical Advisor · Since at least Oct 16, 2026); Lumos Pharma Inc (Chief Medical Officer · Nov 13, 2017 – Feb 1, 2021 · Past)
Chief Medical Officer · Sep 1, 2022 – Feb 25, 2023 · Past
Caroline Code
Other companies: Obsidian Therapeutics, Inc. (VP Corporate Development and Investor Relations · Since at least Aug 5, 2026)
VP Corporate Development & Investor Relations · Since at least Apr 14, 2026
Linda West
Other companies: Context Therapeutics Inc. (Independent Director · Since at least Oct 19, 2021)
Director · Mar 31, 2020 – Jul 1, 2023 · Past
All 19 people
PersonSeat
Mark J. Bachleda
Other companies: Lyell Immunopharma, Inc. (Director · Since at least Jun 9, 2025)
Chief Commercial Officer · Oct 8, 2021 – Mar 16, 2023 · Past
Robert Beardsley
Other companies: Arbutus Biopharma Corporation (Director · Since at least Feb 24, 2025)
Chief Operating Officer · Nov 6, 2019 – Feb 25, 2023 · Past
Dennis RileyChief Scientific Officer · Jan 31, 2020 – Jan 31, 2020 · Past
Jason FullerDirector · Nov 6, 2019 – Nov 6, 2019 · Past
Joel F SussmanChief Accounting Officer · Since at least Nov 6, 2019
Jon T HolmlundChief Medical Officer · Nov 6, 2019 – Feb 28, 2022 · Past
Kevin G LokayDirector · Since at least Nov 6, 2019
Mel SorensenPresident and CEO, Director · Since at least Nov 6, 2019
Michael R FriedmanDirector · Since at least Dec 30, 2024

Open People

Log in to ask 6ix AI your own questions about Galera Therapeutics, Inc.